

12

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

21 Application number: 88902569.8

51 Int. Cl.³: C 07 D 495/04
//A61K31/495

22 Date of filing: 17.03.88

Data of the international application taken as a basis:

66 International application number:
PCT/JP88/00290

67 International publication number:
WO88/07533 (06.10.88 88/22)

30 Priority: 25.03.87 JP 70838/87

43 Date of publication of application:
29.03.89 Bulletin 89/13

64 Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

71 Applicant: Yoshitomi Pharmaceutical Industries, Ltd.
35 Hiranomachi 3-chome Higashi-ku
Osaka-shi Osaka 541(JP)

72 Inventor: NAKAO, Toru
774-22, Oaza-Higashihama
Nakatsu-shi Oita 871(JP)

72 Inventor: MORITA, Kenji
1345, Nakatsu-shi
Oita 871(JP)


72 Inventor: HISADOME, Masao
276-19, Aza-Kamigou Oaza-Mada
Nakatsu-shi Oita 871(JP)

72 Inventor: TAKEHARA, Shuzo
684-1, Shimomiyana 3-chome
Nakatsu-shi Oita 871(JP)

74 Representative: von Kreisler, Alek et al,
Patentanwälte Von
Kreisler-Selting-Werner-Schönwald-Fues-Dallmeyer
Deichmannhaus
D-5000 Köln 1(DE)

54 THIENOCINNOLINE COMPOUNDS AND THEIR MEDICINAL APPLICATION.

57 Thienocinnoline compounds represented by general formula (I)



(I)

(wherein R represents hydrogen, halogen or lower alkyl, Ar represents aryl, heteroaryl, or aryl or heteroaryl having at least one substituent selected from the group consisting of halogen, lower alkyl, lower alkoxy, nitro, amino,

hydroxy, trifluoromethyl and lower alkanoylamino, and ~~---~~ between 5a-position and 6-position represents either a single or a double bond) useful as anti-anxious agents, amnesia treating agents, brain function activating agents, anti-dement agents or bioprotection accelerating agents.

BEST AVAILABLE COPY

TITLE MODIFIED
see front page

SPECIFICATION

Thienocinnoline Compounds and their Pharmaceutical Use

[Technical Field]

This invention relates to thienocinnoline compounds which are novel and of use as pharmaceuticals and their pharmaceutical use.

[Background Art]

Benzodiazepine (BZP) derivatives represented by diazepam have been used long as an antianxiety drug or a therapeutic medicine for sleep disturbance. The recent pharmacological studies have shown that there exist receptors which exhibit a specific affinity for BZP derivatives in the central nervous system [Science, vol. 198, 849 (1977)]. In the studies and researches conducted subsequently, there have been investigated and developed not only BZP derivatives but also the compounds which have structures different from BZP but exhibit a high affinity for BZP receptors and a BZP-like action (BZP agonist), the compounds which exhibit a high affinity for BZP receptors but exhibit a pharmacological action reverse to BZP (BZP inverse-agonist) and the compounds which exhibit a high affinity for BZP receptors but nevertheless exhibit no pharmacological activity themselves and rather show an antagonistic action against the action of the agonist or the inverse-agonist (BZP antagonist) [Advance in Drug Research, vol. 14, 165 (1985)].

Since BZP derivatives which are used as an antianxiety

drug have a sedative action, a muscle-relaxing action and an anticonvulsive action in addition to an antianxiety action, they often cause troubles in terms of side effects such as dizziness and sleepiness. Thus, researches of non-BZP types of compounds aiming at developing selective antianxiety drugs with less side effects are thriving. Nevertheless, there have not been found satisfactory ones yet.

Also, in recent years, amnesia-inducing actions by BZP agonists were found [Nature, vol. 321, 864 (1986)], and there have been reports suggesting the possibility that BZP-antagonists exhibiting an antagonistic action against the amnesic actions induced by BZP agonists and BZP-inverse-agonists exhibiting an action reverse to the amnesic actions by BZP agonists are usable as brain-function activating drugs. [Trends in Neurosciences, vol. 11, 13 (1988)].

In the meantime, in the specification of U.S. Patent No. 4602019 there are disclosed compounds such as 2,4,4a,5-tetrahydro-7-(1H-imidazol-1-yl)-3H-indeno[1,2-c]pyridazin-3-one having a cardiac action and an antihypertensive action. The Journal of Medicinal Chemistry, vol. 24, 830 (1981) discloses compounds such as 2-(4-chlorophenyl)benzothiopyrano-[4,3-c]pyrazol-3-one possessing an immune-suppressing action.


[Disclosure of Invention]

The present inventors have conducted intensive studies for the purpose of developing BZP-agonists, BZP-inverse-agonists or BZP-antagonists having a non-BZP-nucleus which

are useful pharmaceuticals and providing effective compounds and pharmaceuticals.

It has been found that the above-mentioned purpose can be attained according to the present invention described hereinafter.

That is, the first invention is to provide thienocinnoline compounds of the general formula




wherein R stands for hydrogen, a halogen or a lower alkyl, Ar stands for an aryl, a heteroaryl, or an aryl or a heteroaryl having as a substituent at least a halogen, a lower alkyl, a lower alkoxy, nitro, amino, hydroxy, trifluoromethyl and/or a lower alkanoylamino; and the bond ~~====~~ between 5a-position and 6-position represents a single bond or a double bond.

The second invention is to provide pharmaceutical compositions comprising a thienocinnoline compound of the above general formula (I).


The symbols of the general formula (I) and each of the below-mentioned general formulae are defined in detail below. The halogen represents chlorine, bromine, fluorine or the like; the lower alkyl represents an alkyl having 1 to 4

carbon atom(s) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl; the lower alkoxy represents an alkoxy having 1 to 4 carbon atom(s) such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or tert-butoxy; the lower alkanoylamino represents an alkanoylamino having 2 to 5 carbon atoms such as acetylamino, propionylamino, butyrylamino or pivaloylamino; the aryl represents phenyl, naphthyl or the like; and the heteroaryl represents a 5- or 6-membered ring or its fused ring containing 1 to 3 (preferably 1 or 2) hetero atom(s) (e.g. nitrogen, oxygen, sulfur) on the ring such as 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 3- or 4-pyrazolyl, 1- or 2-imidazolyl, 2-, 4- or 5-pyrimidinyl, 3-, 4- or 5-pyridazinyl or 2-, 4- or 5-benzimidazolyl.

The compounds of the general formula (I) can be produced by subjecting to ring-closure reaction a compound of the formula



wherein each of the symbols is as defined above, which can be obtained by reacting a compound of the general formula



wherein R is as defined above, with a hydrazine derivative of the general formula



wherein Ar is defined as above or its acid addition salt.

The reactions proceed by heating under reflux in a suitable solvent, for example, an alcohol solvent such as methanol, ethanol or propanol for 5 to 20 hours to yield the compound of the formula (I) and the compound of the formula (IV).

In case where an acid addition salt of the hydrazine derivative of the general formula (III) is employed, the reaction is conducted in the presence of an acid scavenger (sodium acetate, potassium acetate, sodium bicarbonate, sodium carbonate, potassium carbonate, pyridine, triethylamine, etc.).


When the compound of the general formula (IV) is obtained in the above reaction, the compound of the general formula (I) can be produced by heating the obtained compound of the general formula (IV) under reflux in acetic acid for 5 - 10 hours.

The compound of the general formula (I) wherein the bond


between 5a-position and 6-position is a double bond can be synthesized also by adding bromine in an amount of 1 - 1.5 times mol dropwise to the corresponding compound of the general formula (I) wherein the bond between 5a-position and 6-position is a single bond in acetic acid as the solvent at 20 - 60°C [Journal of Medicinal Chemistry, vol. 14, 262 (1971)] or by reacting the compound of the general formula (I) wherein the bond between 5a-position and 6-position is a single bond with sodium-m-nitrobenzenesulfonate (Bachmann method, The specification of United Kingdom Patent No. 1168291).

The compounds of the general formula (I) which can be produced in the above-mentioned manner can be isolated and purified by a conventional method such as column chromatography or recrystallization.

The compounds of the general formula (II) of this invention are novel compounds which have not been described in any literature. The compounds can be produced by, for example, converting the corresponding compounds of the general formula



wherein R is as defined above, or their acid addition salts to their quaternary ammonium compounds by adding methyl iodide to the compounds of the general formula (V) or their acid addition salts in acetone and retaining the mixture at room temperature for 2 - 5 hours, followed by converting the quaternary ammonium compounds to the corresponding cyano compounds of the general formula



wherein R is as defined above, by adding potassium cyanide or sodium cyanide to the quaternary ammonium compounds in an aqueous methanol and reacting the mixture at 30 - 50°C for 4 - 10 hours, followed by adding the thus-obtained compounds of the general formula (VI) to acetic acid and conc. hydrochloric acid and heating under reflux the mixture for 5 - 12 hours.

For reference's sake, representative examples of the compounds of the general formula (II) are indicated with their physical constant below.

4-Oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid,
m.p. 118 - 120°C

2-Bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-
acetic acid, m.p. 134 - 136°C

2-Methyl-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid, m.p. 117 - 122°C

The preparation of some of the esters of the compounds of the general formula (II) are reported by S. Kukolja et al. in Journal of Medicinal Chemistry, vol. 28, 1986 (1985).

The compounds of the general formula (I) exhibit a high affinity of 10^{-7} - 10^{-9} M to BZP receptors and have an antagonistic action against chemical convulsants such as bicuculline and pentylenetetrazole. They also exhibit an inhibitory action against amnesia induced by electro-convulsive shock.

Furthermore, they exhibit pharmacological actions such as potentiating actions of leukocyte phagocytosis, potentiating actions of macrophage-phagocytosis and protective actions against infection.

The pharmacological actions of the compounds of the present invention are shown with the experimental methods therefor below.

Experimental Example 1 : Displacement ability for Benzodiazepine

The experiment for specific affinity to benzodiazepine receptors was carried out in accordance with the method described in Life Science, vol. 20, 2101 (1977).

The crude synaptosome fraction was isolated from the cerebral cortex of male Wistar rats aged 9 - 10 weeks, and was suspended in 50 mM Tris-hydrochloric acid buffer solution

(pH 7.4) containing 120 mM sodium chloride and 5 mM potassium chloride. These suspensions were used for the experiment.

The test compounds in several different concentrations and tritiated diazepam (in final concentration of 2 nM) were added to the synaptosome suspensions, and the mixtures were incubated at 0°C for 20 minutes. These suspensions were filtered with Whatman GF/B glassfiber filters. After the filters were washed with the above-mentioned buffer solution, the radioactivity left on the filters was measured with the use of a liquid scintillation counter.

Specific binding was determined by subtracting binding in the presence of 10^{-6} M unlabelled diazepam from total binding.

According to the foregoing experimental method, the binding force to benzodiazepine receptors of the compound of the present invention is evaluated from its displacement ability for tritiated diazepam at its binding site, which is represented by K_i value (nM).

The results of the experiment are shown in Table 1.

Table 1

Test compound (Example No.)	Affinity to BZP Receptors, K_i (nM)
3	280
4	30
5	18
6	12

7	60
9	12
10	7
11	4.5
14	5.1
24	10

Experimental Example 2 : Anti-Bicuculline Action

The anti-bicuculline action test was carried out in accordance with the method described in Life Science, vol. 21, 1779 (1977).

Male ddY mice weighing 20 - 28 g, 7 - 14 animals per group, were used. One hour after the oral administration of the test compounds, (+) bicuculline was intravenously administered at the dosage of 0.6 mg/kg, and 50% effective concentration (ED_{50}) was estimated by examining whether the tonic convulsion within 5 minutes was caused or not. The result was that the ED_{50} values of the compounds of Example 6, 10 and 24 were 50 - 100 mg.

Experimental Example 3 : Action on Experimental Amnesia

The experiment was carried out in accordance with the method described by Sara in Psychopharmacologia, vol. 36, 59 (1974).

Male ddY mice weighing 23 - 26 g, 20 animals per group, were used, and a step-through passive avoidance reflex practicing box consisting of illuminated chamber and dark chamber was used as the experimental apparatus. As the

acquisition trial of passive avoidance reflex, the animals were placed in the illuminated chamber and then allowed to enter the dark one. As soon as the animals entered the dark chamber, footshock was applied to the mouse. Experimental amnesia was caused by applying electroconvulsive shock [ECS] soon after the acquisition trial. As the experimental trial, the animals were placed in the illuminated chamber three hours after the acquisition trial, and the time which the animals took to enter the dark chamber (latency) was measured until 600 seconds. The test compounds were administered intraperitoneally (i.p.) immediately after the application of ECS.

For the evaluation of the effects, antagonistic actions against the reduction in latency, caused by the application of ESC were examined. Measured was the minimum effective dose (MED) at which a significant antagonistic action was exhibited in the mouse treated with the test compounds as compared with controls. The results are summarized in Table 2.

Table 2

Test compound (Example No.)	Anti-amnesia Action MED (mg/kg, ip)
3	0.1
4	0.5
5	0.25
7	<0.5

9	0.5
14	0.25

Experimental Example 4 : Action on Leukocyte-phagocytosis

The experiment was performed in accordance with the method by Stossel et al. [Journal of Clinical Investigation, vol. 51, 615 (1972)].

ICR mice weighing 30 - 35 g were intraperitoneally administered with glycogen. Three hours later, the leukocytes in the abdominal cavity were collected. A leukocyte suspension of 5×10^6 cells/ml was prepared and 200 μ l of the test compound was added to the cell suspension, followed by further addition of 100 μ l of mouse serum and 100 μ l of dead yeast (1×10^8 particles/ml) thereto. The mixture was incubated at 37°C for 20 minutes. By observing more than 200 leukocytes in the reaction mixture under a microscope (400 magnifications), the number of the leukocytes which had phagocytosed at least one dead yeast was counted. The ratio of the number of phagocytic leukocytes treated with 0.1 μ M of the test compounds relative to that of phagocytic leukocytes of controls was estimated. The potentiating actions on phagocytosis of the compounds of Examples 1 and 9 were 160% and 158% respectively.

Experimental Example 5 : Action on Macrophage-phagocytosis

Casein sodium was intraperitoneally administered to rats. Three to four days later, peritoneal macrophages

were collected. The phagocytosis was examined, and the relative ratio of phagocytic macrophages of the rat treated with 0.1 μ M of the test compound was calculated in the same manner as Experimental Example 4. The potentiating actions on phagocytosis of the compounds of Example 2, 8 and 10 were 146%, 167% and 148% respectively.

Experimental Example 6 : Infection-protective Action

Cyclophosphamide was intraperitoneally administered to male ICR mice (weighing 23 - 27 g, aged 5 weeks) at the dosage of 200 mg/kg. Four days later, 1×10^{-8} CFU of E. coli 0-111 strain was subcutaneously inoculated into the mice (Controls). The test compounds (3 mg/kg) were orally administered to the mice for 3 days from the following day of the administration of cyclophosphamide. The survival rate of the treated mice relative to controls 7 days after the inoculation of E. coli was compared. Thus, the compounds of Examples 2, 8 and 11 exhibited significant increasing effects on survival rate.

As apparent from the foregoing various pharmacological studies including experiments, the compounds (I) of the present invention have a high affinity for BZP receptors and exhibit an antagonistic action against chemical convulsion-inducing agents such as bicuculline and pentylenetetrazole, whereas they influence to a small extent on somatic functions such as muscle-relaxing actions. Thus, they are useful as an antianxiety agent. Also, since they possess an inhibitory action on amnesia induced by electroconvulsive shock, they

are useful as an amnesia-treating drugs, brain function-activating drugs and antidementiac drugs. They are also of value as an antidote for excessive administration of or toxicosis by existent antianxiety drugs such as diazepam. Besides, in view of the fact that they have leukocyte-phagocytosis-potentiating actions, macrophage-phagocytosis-potentiating actions, infection-protective actions and other pharmacological actions, they are useful as a potentiating agent of biological protection.

When the compounds of the general formula (I) are used as pharmaceuticals, a therapeutically effective amount of the compounds and adequate pharmacologically acceptable additives such as excipient, carrier, diluent and so on are mixed to be formulated into a form such as tablets, capsules, granules, syrups, injectable solutions, suppositories, dispersible powders or the like and are administered in a form mentioned above. The dosage, for example, in the case of oral administration, is generally about 5 - 500 mg daily per adult, which is once a day or in divided doses several times a day administered.

[Example]

Below, this invention is more specifically described with working examples, which are not to be construed as limitative.

Example 1

4-Oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid

(3.7 g) and 1.9 ml of phenylhydrazine are dissolved in 50 ml of butanol. After the mixture is stirred at an outside temperature of 90 to 100°C for 3 hours, the solvent is distilled off. The residue is purified by column chromatography to give crude crystals, which are recrystallized from ethanol to afford 1.2 g of 8-phenyl-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 117 - 119°C.

Example 2

Using 4-chlorophenylhydrazine instead of phenylhydrazine as used in Example 1, the reaction and procedure conducted by the same method as that of Example 1 yield 8-(4-chlorophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 169 - 171°C.

Example 3

The reaction and procedure conducted in the same manner as that of Example 1 using 2-hydrazinopyridine in place of phenylhydrazine as used in Example 1 give 8-(2-pyridyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 135 - 136°C.

Example 4

The reaction and procedure conducted by the same method as that of Example 1 using 2-bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid instead of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 1 give 2-bromo-8-phenyl-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 131 - 133°C.

Example 5

By following the reaction and procedure conducted by the same method as that of Example 1 using 2-methyl-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid in place of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 1 give 2-methyl-8-phenyl-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 106 - 108°C.

Example 6

By following the reaction and procedure conducted by the same method as that of Example 1 using 2-bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid instead of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 1 and 4-chlorophenylhydrazine instead of phenylhydrazine, 2-bromo-8-(4-chlorophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 115 - 117°C is produced.

Example 7

By conducting the reaction and procedure by the same method as that of Example 1 using 2-bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid instead of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 1 and 2-hydrazinopyridine instead of phenylhydrazine as used in Example 1, 2-bromo-8-(2-pyridyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 138 - 141°C is produced.

Example 8

In 50 ml of butanol are dissolved 3.0 g of 4-oxo-

4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid and 2.5 g of 4-methylphenylhydrazine hydrochloride, where to 1.3 g of sodium acetate is added. The mixture is heated under reflux for 2 hours. After the solvent is distilled off, water is added thereto. The mixture is extracted with chloroform, washed with water and dried over anhydrous magnesium sulfate. The solvent is distilled off. The obtained crude crystals are purified by column chromatography, and recrystallized from ethanol to yield 2.3 g of 8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 157 - 160°C.

Example 9

The reaction and procedure by the same method as that of Example 8 using 4-methoxyphenylhydrazine hydrochloride in place of 4-methylphenylhydrazine hydrochloride as used in Example 8 is conducted to afford 8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 190 - 192°C.

Example 10

By following the reaction and procedure by the same method as that of Example 8 using 2-bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid in place of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 8, 2-bromo-8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 142 - 144°C is produced.

Example 11

By following the reaction and procedure by the same

method as that of Example 8 using 2-bromo-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid instead of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 8 and 4-methoxyphenylhydrazine hydrochloride instead of 4-methylphenylhydrazine hydrochloride as used in Example 8, 2-bromo-8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 155 - 156°C is produced.

Example 12

By following the reaction and procedure by the same method as that of Example 8 using 2-methyl-4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid instead of 4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-5-acetic acid as used in Example 8 and 4-chlorophenylhydrazine hydrochloride instead of 4-methylphenylhydrazine hydrochloride, 2-methyl-8-(4-chlorophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 137 - 139°C is obtained.

The following compounds can be obtained in the same manner as in the above examples.

Example 13

2-Methyl-8-(2-pyridyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 143 - 145°C.

Example 14

2-Methyl-8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 133 - 135°C.

Example 15

8-(4-Nitrophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-

h]cinnolin-7-one.

Example 16

8-(3-Trifluoromethylphenyl)-4,5,5a,6,7,8-hexahydrothieno-
[2,3-h]cinnolin-7-one.

Example 17

8-(4-Aminophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-
h]cinnolin-7-one.

Example 18

8-(4-Acetylaminophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-
h]cinnolin-7-one.

Example 19

8-(4-Hydroxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-
h]cinnolin-7-one, m.p. 268 - 269°C.

Example 20

2-Methyl-8-(3-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno-
[2,3-h]cinnolin-7-one.

Example 21

2-Methyl-8-(4-nitrophenyl)-4,5,5a,6,7,8-hexahydrothieno-
[2,3-h]cinnolin-7-one.

Example 22

2-Methyl-8-(4-acetylaminophenyl)-4,5,5a,6,7,8-hexahydro-
thieno[2,3-h]cinnolin-7-one.

Example 23

2-Methyl-8-(4-hydroxyphenyl)-4,5,5a,6,7,8-hexahydro-
thieno[2,3-h]cinnolin-7-one.

Example 24

2-Methyl-8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydro-thieno[2,3-h]cinnolin-7-one, m.p. 120 - 122°C.

Example 25

8-(3-Methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 135 - 137°C.

Example 26

8-(2-Methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, m.p. 148 - 150°C.

Example 27

8-(4,6-Dimethyl-2-pyrimidinyl)-4,5,5a,6,7,8-hexahydro-thieno[2,3-h]cinnolin-7-one, m.p. 230 - 232°C.

Example 28

8-(6-Chloro-3-pyridazinyl)-4,5,5a,6,7,8-hexahydro-thieno[2,3-h]cinnolin-7-one, m.p. 263 - 264°C (decomposition).

Example 29

8-(4-Methoxy-2-pyrimidinyl)-4,5,5a,6,7,8-hexahydro-thieno[2,3-h]cinnolin-7-one.

Example 30

In 50 ml of acetic acid is dissolved 1.6 g of 2-methyl-8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one as obtained in Example 24, and 0.2 ml of bromine is added to the solution while stirring at room temperature. The mixture is mixed at 80 - 90°C for 30 minutes. After the solvent is distilled off, the obtained crystals are purified by way of silica gel column chromatography, followed by recrystallization from isopropyl alcohol

to give 0.8 g of 2-methyl-8-(4-methylphenyl)-4,5,7,8-tetrahydrothieno[2,3-h]cinnolin-7-one, m.p. 160 - 162°C.

Example 31

Formulation Example

Tablets containing 10 mg of a compound of the general formula (I) are prepared in accordance with the following formulation.

Compound of formula (I)	10.0 mg
Lactose	58.5 mg
Corn starch	25.0 mg
Crystalline cellulose	20.0 mg
Polyvinylpyrrolidone K-30	2.0 mg
Talc	4.0 mg
Magnesium stearate	0.5 mg
	120.0 mg


The compound of the formula (I) is pulverized by an atomizer into fine powders below 10 μ in average particle diameter, which are admixed with lactose, corn starch and crystalline cellulose sufficiently in a kneading machine, and further kneaded with polyvinylpyrrolidone paste. The kneaded mixture is passed through a sieve of 200 mesh, dried at 50°C and passed through a sieve of 24 mesh. Talc and magnesium stearate are mixed therewith and the mixture is compressed into 120.0 mg tablets with a punch of 8 mm in diameter. These tablets are, if desired, subjected to sugar-coating or film-coating.

0308515

While the present invention has been adequately and sufficiently described in the foregoing specification including examples, the description can be changed or modified within the spirit and scope of this invention.

Claims

1. A thienocinnoline compound of the general formula



wherein R is hydrogen, a halogen or a lower alkyl, Ar is an aryl, a heteroaryl, or an aryl or a heteroaryl which has as a substituent at least a halogen, a lower alkyl, a lower alkoxy, nitro, amino, hydroxy, trifluoromethyl and/or a lower alkanoylamino; and the bond ----- between 5a-position and 6-position is a single bond or a double bond.

2. A compound as claimed in Claim 1 which is selected from a group consisting of 8-(2-pyridyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-bromo-8-phenyl-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-methyl-8-phenyl-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-bromo-8-(4-chlorophenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-bromo-8-(2-pyridyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-bromo-8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one, 2-bromo-8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-

7-one, 2-methyl-8-(4-methoxyphenyl)-4,5,5a,6,7,8-hexahydro-thieno[2,3-h]cinnolin-7-one and 2-methyl-8-(4-methylphenyl)-4,5,5a,6,7,8-hexahydrothieno[2,3-h]cinnolin-7-one.

3. A pharmaceutical composition comprising a compound as claimed in Claim 1 or Claim 2 and pharmaceutical additives.

4. An antianxiety drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

5. An amnesia-treating drug, a brain function-activating drug or an antidementiac drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

6. A potentiating agent of biological protection comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP88/00290

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl ⁴ C07D495/04//A61K31/495		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC	C07D495/04, A61K31/495	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	JP, B1, 57-45754 (Yoshitomi Pharmaceutical Industries, Ltd.) 29 September 1982 (29. 09. 82) Page 1, right column, lines 15 to 31, page 2, right column, lines 34 to 41 (Family: none)	1-2
Y	JP, B1, 57-45755 (Yoshitomi Pharmaceutical Industries, Ltd.) 29 September 1982 (29. 09. 82) Page 2, left column, lines 15 to 32, page 3, left column, lines 18 to 26 (Family: none)	1-2
Y	JP, A, 61-56169 (Yoshitomi Pharmaceutical Industries, Ltd.) 20 March 1986 (20. 03. 86) Claim, page 3, lines 26 to 32 & GB, A, 2185977	1-2
<p>¹⁰ Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
June 6, 1988 (06. 06. 88)	June 20, 1988 (20. 06. 88)	
International Searching Authority	Signature of Authorized Officer	
Japanese Patent Office		

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.